<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Hydromorphone - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../style.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Hydromorphone</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../index.html">Home</a>
        <a class="btn small" href="../medications.html">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Analgesia / Anti-inflammatory</div>
      <h1>Hydromorphone</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Hydromorphone 1mg/mL Injection 1mL</li>
          <li>Hydromorphone 2mg Tablets</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <ul>
          <li><strong>Moderate to severe acute pain (opioid-naive; oral)</strong>
            <ul>
              <li>Initial: 1–2 mg PO every 4–6 hours as needed</li>
              <li>Titrate carefully based on response and tolerability</li>
              <li>Use lowest effective dose for shortest duration</li>
            </ul>
          </li>
          <li><strong>Moderate to severe acute pain (opioid-naive; IM/SC)</strong>
            <ul>
              <li>Initial: 0.5–1 mg IM/SC every 4–6 hours as needed</li>
              <li>Onset ~15 minutes IM; duration ~4–5 hours</li>
              <li>Lower doses in elderly or debilitated patients (0.25–0.5 mg)</li>
            </ul>
          </li>
          <li><strong>Moderate to severe acute pain (opioid-tolerant)</strong>
            <ul>
              <li>Individualize dose based on prior opioid use and equianalgesic conversion</li>
              <li>Hydromorphone is ~5–7 times more potent than oral morphine</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Moderate to severe acute pain (trauma, postoperative, renal colic, musculoskeletal injury)</li>
          <li>Severe pain not controlled by non-opioid analgesics</li>
          <li>Cancer pain or palliative care (provider-directed; usually chronic dosing)</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Hypersensitivity to hydromorphone or opioid components</li>
          <li>Respiratory depression or severe respiratory compromise (COPD exacerbation, severe asthma, etc.)</li>
          <li>Acute or severe bronchial asthma in unmonitored setting</li>
          <li>Paralytic ileus or GI obstruction</li>
          <li>CNS depression, head injury with altered mental status or increased ICP (can mask neurologic changes)</li>
          <li>Concurrent CNS depressants (benzodiazepines, alcohol): increased respiratory depression and sedation risk</li>
          <li>Elderly, debilitated, or renal/hepatic impairment: use lower doses and titrate carefully</li>
          <li>Risk of opioid use disorder: assess history and monitor closely</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>Respiratory depression (dose-dependent; life-threatening if severe)</li>
          <li>Sedation, drowsiness, dizziness</li>
          <li>Nausea, vomiting, constipation</li>
          <li>Pruritus</li>
          <li>Hypotension, bradycardia (especially with rapid IV administration or volume depletion)</li>
          <li>Physical dependence and withdrawal with prolonged use</li>
          <li>Risk of opioid use disorder</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li><strong>Oral:</strong> Give with water; may take with food to reduce nausea</li>
          <li><strong>IM/SC injection:</strong> Inject deep IM or SC; rotate sites if repeated dosing</li>
          <li>Avoid IV route in non-monitored settings (risk of severe respiratory depression, hypotension)</li>
          <li>Have naloxone available for opioid reversal in case of overdose/severe respiratory depression</li>
          <li>Titrate dose to effect; reassess pain and sedation before each subsequent dose</li>
          <li>Educate patient: avoid alcohol, CNS depressants, driving, operating machinery</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Pain relief (use pain scale; reassess 30–60 min after dose)</li>
          <li>Respiratory rate and depth (monitor closely; hold dose if RR &lt;10/min or shallow breathing)</li>
          <li>Level of sedation (use sedation scale; stop opioid if oversedated)</li>
          <li>Vital signs (BP, HR, O2 saturation when available)</li>
          <li>Nausea/vomiting (consider antiemetic if needed)</li>
          <li>Bowel function (start bowel regimen if prolonged use anticipated)</li>
          <li>Watch for signs of overdose: severe sedation, pinpoint pupils, respiratory depression (treat with naloxone and supportive care)</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>Use for severe pain when non-opioid analgesics insufficient; assess risk vs benefit carefully</li>
          <li>Start low, go slow, especially in opioid-naive or elderly patients</li>
          <li>Ensure naloxone is readily accessible; know dose and administration</li>
          <li>Document pain score, dose, time, route, and response clearly</li>
          <li>If limited monitoring capability: use conservative dosing and monitor respiratory status closely</li>
          <li>Avoid in head injury if neurologic assessment is critical and limited</li>
          <li>Plan for bowel regimen if multiple doses anticipated</li>
          <li>If prolonged use needed: consider evacuation for comprehensive pain management</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (hydromorphone tablets): <a href="https://pdf.hres.ca/dpd_pm/00067991.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00067991.PDF</a></li>
          <li>Health Canada product monograph (hydromorphone injection): <a href="https://pdf.hres.ca/dpd_pm/00067992.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00067992.PDF</a></li>
          <li>Medscape - Hydromorphone: <a href="https://reference.medscape.com/drug/dilaudid-exalgo-hydromorphone-343310" target="_blank" rel="noopener">https://reference.medscape.com/drug/dilaudid-exalgo-hydromorphone-343310</a></li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
